OR WAIT null SECS
There is a great need for sensitive, precise, and easily accessible analytical detection techniques for protein sequencing.
The emergence of mRNA vaccines and cell and gene therapies has pushed innovation in analytical methods.
Effective analytics will eliminate failures, deviations, and non-conformances.
May 21, 2009
Also, Oxford BioTherapeutics forms drug development pact with GSK; Avila Therapeutics names CEO; more...
May 14, 2009
The first project report on FDA's Sentinel website, discusses the evaluation of existing methods for safety signal identification.
On May 7, 2009, as part of the President's fiscal year (FY) 2010 budget, the US Food and Drug Administration requested a budget of $3.2 billion, which is 19% more than the agency's current budget.
Also, Takeda to consolidate operations in Ireland; FDA to redesign website; Archemix names president and CEO; more...
May 07, 2009
Also, Oxford BioMedica forms collaboration with sanofi-aventis; FDA requires labeling changes for botulinum toxin producs; C. Richter King joins IAVI; more...
May 02, 2009
The president of BIO proposes the ingredients needed for industry growth.
The authors describe the importance of a rapid and an abbreviated screening strategy by initial solvent screening in 20-mL scintillation vials.
Manufacturers of therapeutic monoclonal antibodies consider new paradigms in purification technologies.
The organizations' presidents discuss market exclusivity, approval processes, and pending legislation.
Technology can solve enterprise-level problems.